Recombivax HB consists of each 1 mL contains 10 µg hepatitis B surface antigen
Recombivax HB is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus.
Recombivax HB is administered as an intramuscular injection
Recombivax HB is approved for use in individuals of all ages.
Recombivax HB Dialysis Formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older.
Infants, Children, Adolescents: 0–19 years of age (Pediatric/adolescent formulation)5 mcg (0.5 mL) 3 doses at 0, 1, and 6 months
Adolescents: 11 through 15 years of age (Adult formulation)10 mcgc (1.0 mL) 2 doses at 0 and 4–6 months
Adults: ≥20 years of age (Adult formulation)10 mcgc (1.0 mL) 3 doses at 0, 1, and 6 months
Predialysis and Dialysis Patients: (Dialysis formulation)40 mcg (1.0 mL) 3 doses at 0, 1, and 6 months